和黄医药(00013.HK) 宣布，与阿斯利康(AZN.US) 共同开发的口服间质-上皮转化因子(MET)酪氨酸激酶抑制剂(TKI)“沃瑞沙”，用于治疗具有MET外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者，新适应症上市申请已获中国国家药监局批准。
国家药监局亦将早前沃瑞沙在经治患者中的附条件批准转为常规批准，意味着沃瑞沙在中国的新适应症将扩展至同时涵盖初治和经治患者。
和黄医药研发负责人兼首席医学官石明表示，未来将进一步推动研究并扩展沃瑞沙的可及性，将继续探索沃瑞沙在其他MET驱动疾病中的应用。阿斯利康中国肿瘤业务总经理关冬梅指出，通过与和黄医药合作，可推动沃瑞沙用于解决对EGFR-TKI1的耐药性，为治疗MET突变和扩增癌症开启新的可能性。(gc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-13 16:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.